Bass on pharma IPRs: individual self-interest, properly directed, benefits society writ large.
See post on PatentlyO titled Kyle Bass’s Response to Motions about Abuse of IPR in IPR2015-01092 . Onw notes that IPR2015-01092 concerns Celgene's US Patent 6,045,501.
Separately, see the Bloomberg piece Will Kyle Bass’s Drug Patent Gambit Pay Off? He’ll Soon Find Out .
This article concerns Bass's challenge to a patent related to the drug Ampyra of the company Acorda (US Patent No. 8,663,685 ; IPR2015-00720 ):
The U.S. Patent and Trademark Office is expected to say by Wednesday whether there’s merit in the first of Bass’s 20 drug-patent challenges, this one targeting Acorda Therapeutics Inc.’s multiple sclerosis drug Ampyra. The agency will institute a formal review if it thinks Bass has a chance of winning.
See also: https://www.docketalarm.com/cases/PTAB/IPR2015-00720/Inter_Partes_Review_of_U.S._Pat._8663685/02-10-2015-PET-3366/Petition-1-Petition_for_Inter_Partes_Review_of_US_Patent_No_8%2C663%2C685/
See also: http://www.pharmapatentsblog.com/2015/05/05/keeping-up-with-kyle-bass/
Separately, see the Bloomberg piece Will Kyle Bass’s Drug Patent Gambit Pay Off? He’ll Soon Find Out .
This article concerns Bass's challenge to a patent related to the drug Ampyra of the company Acorda (US Patent No. 8,663,685 ; IPR2015-00720 ):
The U.S. Patent and Trademark Office is expected to say by Wednesday whether there’s merit in the first of Bass’s 20 drug-patent challenges, this one targeting Acorda Therapeutics Inc.’s multiple sclerosis drug Ampyra. The agency will institute a formal review if it thinks Bass has a chance of winning.
See also: https://www.docketalarm.com/cases/PTAB/IPR2015-00720/Inter_Partes_Review_of_U.S._Pat._8663685/02-10-2015-PET-3366/Petition-1-Petition_for_Inter_Partes_Review_of_US_Patent_No_8%2C663%2C685/
See also: http://www.pharmapatentsblog.com/2015/05/05/keeping-up-with-kyle-bass/
posted by Lawrence B. Ebert at 9:41 AM
0 Comments:
Post a Comment
<< Home